Friday, December 15, 2017 10:15 PM ET
Significant Insider Buying in Shares of REATA Pharmaceuticals (RETA)
There were substantial insider purchases of REATA Pharmaceuticals shares today, as shown in filings with the SEC as three insiders — CPMG Inc, 10% Owner and Director, R Kent McGaughy Jr, 10% Owner and Director, and James W Traweek Jr, 10% Owner — bought 600,000 shares in the company having a net market value of approximately $14,875,219. This is the first insider buy/sell trade in the past 90 days.
The number of insider buy/sell trades at REATA Pharmaceuticals is above that of the 278 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 316 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by REATA Pharmaceuticals insiders is lower than its peers. Within the peer group there were 37,233,189 shares purchased and 40,450,449 shares sold with company insiders selling 10,181 shares on average over this time period.
Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data obtained in creating and writing this story.
Today’s Insider Activity
* CPMG Inc, 10% Owner and Director, bought 200,000 shares
* R Kent McGaughy Jr, 10% Owner and Director, bought 200,000 shares
* James W Traweek Jr, 10% Owner, bought 200,000 shares
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.